AbbVie Inc (4AB)

TradeGate
Currency in EUR
Disclaimer
130.40
+4.10(+3.25%)
Delayed Data
Day's Range
126.30130.60
52 wk Range
118.80159.00
Bid/Ask
130.30 / 130.50
Prev. Close
126.3
Open
126.4
Day's Range
126.3-130.6
52 wk Range
118.8-159
Volume
3,616
Average Vol. (3m)
2,714
1-Year Change
-17.58%
Shares Outstanding
1,765,537,421
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
167.21
Upside +17.75%

People Also Watch

170.16
AXP
+1.63%
923.58
AVGO
-1.83%
551.11
UNH
+3.02%
167.05
PEP
+0.70%
188.92
AAPL
-0.24%
How do you feel today about 4AB?
Vote to see community's results!
or

AbbVie Inc Company Profile

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Employees
50000